SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Michael L who wrote (19803)3/17/1999 3:20:00 PM
From: Colby  Read Replies (3) of 23519
 
Wednesday March 17, 8:31 am Eastern Time

Company Press Release

VISX CEO Mark Logan and Wilson, Sonsini, Goodrich & Rosati Partner Mario Rosati Join the VIVUS Board of Directors

MOUNTAIN VIEW, Calif.--(BW HealthWire)--March 17, 1999--VIVUS, Inc. (Nasdaq:VVUS - news) has named Mark Logan, Chairman, President and Chief Executive Officer of VISX, Inc. and Mario Rosati, a partner at Wilson, Sonsini, Goodrich & Rosati to the Company's Board of Directors. Logan and Rosati will fill the board seats vacated due to the resignations of Richard Casey and Elizabeth Fetter. All Board changes are effective immediately.

Mark Logan has served as the Chairman of the Board, President and CEO of VISX, Inc., a medical device company, since 1994. From January 1992 to October 1994, he was Chairman of the Board and Chief Executive Officer of INSMED Pharmaceuticals, Inc. Previously, Logan held senior management positions at Bausch and Lomb, Inc., Becton, Dickinson & Co., and American Home Products, Inc. Logan received a B.A. from Hiram College and a P.M.D. from Harvard Business School.

Mario Rosati has held the position of Secretary of VIVUS since April 1991, while serving as a partner at Wilson, Sonsini, Goodrich & Rosati, a law firm that provides counsel to VIVUS. Additionally, Rosati is a member of the Board of Directors of several high technology companies.

Founded in 1991, VIVUS, Inc. is a leader in the development of advanced therapeutic systems for the treatment of erectile dysfunction, commonly referred to as impotence. VIVUS has pioneered a novel therapy for erectile dysfunction known as the transurethral system for erection. This therapy consists of a proprietary, non-invasive drug delivery system that delivers pharmacologic agents via the urethra.

Note to editors and investors: Additional written materials, recent releases and Company information are available through a variety of sources, including the VIVUS home page (www.vivus.com) and the VIVUS Fax-On-Demand Service (1-888-329-5719).
------------------------------------------------------------------------
Contact:

VIVUS
Nina W. Ferrari, 650/934-5200
IR@VIVUS.com
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext